LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "cell engagers" as a keyword



Bispecific T‐cell engagers for treatment of multiple myeloma

Sign Up to like & get
recommendations! Published in 2022 at "American Journal of Hematology"

DOI: 10.1002/ajh.26628

Abstract: Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of… read more here.

Keywords: cell engagers; cell; multiple myeloma; bispecific cell ... See more keywords

Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden

Sign Up to like & get
recommendations! Published in 2024 at "Cancer Medicine"

DOI: 10.1002/cam4.7048

Abstract: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T‐cell… read more here.

Keywords: effectiveness infectious; multiple myeloma; cell engagers; bcma cell ... See more keywords

Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies

Sign Up to like & get
recommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"

DOI: 10.1007/s00262-018-2181-5

Abstract: The recruitment of T-cells by bispecific antibodies secreted from adoptively transferred, gene-modified autologous cells has shown satisfactory results in preclinical cancer models. Even so, the approach’s translation into the clinic will require incremental improvements to… read more here.

Keywords: light cell; cell engagers; based immunotherapy; gene based ... See more keywords
Photo by nci from unsplash

T cell engagers in solid tumors kick the door down.

Sign Up to like & get
recommendations! Published in 2021 at "Cancer cell"

DOI: 10.1016/j.ccell.2021.10.005

Abstract: Tebentafusp, a T cell-redirecting, bispecific-antibody-targeting, HLA∗02:01-restricted gp100 peptide and CD3, induces T cells to kill glycoprotein 100 (gp100)-expressing tumor cells. Tebentafusp is the first T cell engager to show a statistically significant overall survival improvement for the treatment… read more here.

Keywords: engagers solid; solid tumors; cell engagers; tumors kick ... See more keywords

Polymer Micropatches as B-Cell Engagers.

Sign Up to like & get
recommendations! Published in 2024 at "ACS applied materials & interfaces"

DOI: 10.1021/acsami.4c04385

Abstract: B cells, despite their several unique functionalities, remain largely untapped for use as an adoptive cell therapy and are limited to in vitro use for antibody production. B cells can be easily sourced, they possess… read more here.

Keywords: cell engagers; micropatches cell; mace; polymer micropatches ... See more keywords

Trispecific T Cell Engagers in Hematological Malignancies: Advancing Beyond Bispecific Antibodies

Sign Up to like & get
recommendations! Published in 2025 at "Seminars in Hematology"

DOI: 10.1053/j.seminhematol.2025.11.002

Abstract: The success of bispecific T cell engagers (BiTEs) in hematological malignancies has catalyzed the development of trispecific antibodies that simultaneously target 3 molecular entities. These next-generation immunotherapeutics address the key limitations of bispecific constructs including… read more here.

Keywords: engagers hematological; cell engagers; hematological malignancies; cell ... See more keywords

Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development

Sign Up to like & get
recommendations! Published in 2022 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2022.2098674

Abstract: ABSTRACT Introduction T cell engagers are a class of bispecific molecules that induce highly potent T cell-dependent cytotoxicity by bringing T cell activating receptors into proximity with cancer-associated cell surface antigens. However, because of their… read more here.

Keywords: cell; development; active cell; solid tumors ... See more keywords

Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database

Sign Up to like & get
recommendations! Published in 2025 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2025.2470875

Abstract: ABSTRACT Background T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequately characterized. Research design and methods Using the FDA Adverse Event… read more here.

Keywords: faers database; adverse events; cell engagers; comprehensive analysis ... See more keywords

Development of T-cell engagers selective for cells co-expressing two antigens

Sign Up to like & get
recommendations! Published in 2022 at "mAbs"

DOI: 10.1080/19420862.2022.2115213

Abstract: ABSTRACT T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments for hematological cancers. While the utility of TCEs in solid malignancies is being explored, toxicities arising from antigen expression on normal tissues have slowed or… read more here.

Keywords: cell; development; expressing two; cells expressing ... See more keywords

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

Sign Up to like & get
recommendations! Published in 2024 at "mAbs"

DOI: 10.1080/19420862.2024.2315640

Abstract: ABSTRACT Natural killer (NK) cells emerged as a promising effector population that can be harnessed for anti-tumor therapy. In this work, we constructed NK cell engagers (NKCEs) based on NKp30-targeting single domain antibodies (sdAbs) that… read more here.

Keywords: architecture; antibody architecture; cell engagers; cell ... See more keywords

Innovative strategies for T cell engagers for cancer immunotherapy

Sign Up to like & get
recommendations! Published in 2025 at "mAbs"

DOI: 10.1080/19420862.2025.2531223

Abstract: ABSTRACT T cell engagers (TCEs) are a promising class of cancer immunotherapy that re-direct T cells to kill tumor cells. However, their clinical application is limited by several challenges, including cytokine release syndrome (CRS), on-target… read more here.

Keywords: cancer; cell engagers; cancer immunotherapy; tumor ... See more keywords